



BRITISH GENERIC MANUFACTURERS ASSOCIATION

June 15, 2015

FMD to feature as part of next BGMA/MHRA Quality Forum

The British Generic Manufacturers Association (BGMA) will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Wednesday, July 8th.

The Quality Forum was launched last year with the MHRA to focus on ensuring the manufacturing quality of generic medicines in the UK.

The group meets three times a year to share and discuss the latest issues and provide an open channel between industry and the regulator.

The forum brings together generic medicines companies, those who provide manufacturing and quality control services, as well as the MHRA. Topics covered have included data integrity, current approaches to inspection, trends and the auditing that companies perform themselves.

The next meeting will feature updates on the Falsified Medicines Directive, advice on avoiding cross contamination as well as a focus on elemental impurities. There will also be an update from the European Generics Association (EGA) on their work into good clinical practice (GCP).

Paul Fleming, the BGMA's Technical Director, said: "There are a number of important industry activities and regulatory updates which will be impacting both at a UK and European level and it is vital that companies are able to meet with the MHRA to discuss challenges and best practice. This forum is now well established as an important means for sharing of information."

The forum is open to members and associate members of the BGMA and for further information please contact email jeremy.durrant@britishgenerics.co.uk. Full information is available on the website www.britishgenerics.co.uk.

ENDS

For further information contact:

Jeremy Durrant, 020 7866 7883 / 07792 918648

jeremy.durrant@britishgenerics.co.uk

Notes for Editors:

Press Release

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds of all medicines dispensed by the NHS are generics yet they cost only around 29% of the NHS drugs bill, a saving of more than £12.5billion in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.